title: Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer.
abstract: Although Th22 and Th17 cells have been reported to play critical roles during autoimmunity and inflammation, information on their role in cancer-immunity is limited. In this study, we investigated clinical relevance of circulating Th22 and Th17 cells in patients with gastric cancer (GC). Using multi-color flow cytometry and PMA stimulation, we determined the levels of Th22, Th17 and Th1 cells in the peripheral blood of 32 GC patients and 19 healthy donors, and evaluated their correlations with tumor stage and overall survival. Compared with healthy donors, the frequencies of circulating CD4(+)IL-22(+) T cells, CD4(+)IL-17(+) T cells, Th22 (CD4(+)IL-22(+)IL-17(-)INF-γ(-)) cells, Th17 (CD4(+)IL-17(+)INF-γ(-)) cells were increased in patients with GC, but there was no significant differences in the frequencies of CD4(+)IFN-γ(+) T cells and Th1 (CD4(+)IL-17(-)INF-γ(+)) cells. Th22 cells showed positive correlation with Th17 cells and CD4(+)IL-17(+) T cells in patients with GC. Furthermore, the frequencies of Th22 and Th17 cells were significantly higher in stage III-IV GC patients versus stage I-II and correlated with patients' overall survival. These data suggest that circulating Th22 cells as well as Th17 cells are increased in the peripheral blood of GC patients with tumor progression, and that these cells may be promising novel clinical markers for GC.
authors: Department of Clinical Microbiology and Immunology, College of Medical Laboratory Science, Third Military Medical University, No.30 Gaotanyan street, Chongqing, 400038, People's Republic of China.
authors: Tao
authors: T
authors: Liu
authors: Liusheng
authors: L
authors: Peng
authors: Peiwu
authors: P
authors: Yu
authors: Yongliang
authors: Y
authors: Zhao
authors: Yun
authors: Y
authors: Shi
authors: Xuhu
authors: X
authors: Mao
authors: Weisan
authors: W
authors: Chen
authors: Ping
authors: P
authors: Cheng
authors: Tingting
authors: T
authors: Wang
authors: Na
authors: N
authors: Chen
authors: Jinyu
authors: J
authors: Zhang
authors: Xiaofei
authors: X
authors: Liu
authors: Na
authors: N
authors: Li
authors: Gang
authors: G
authors: Guo
authors: Wende
authors: W
authors: Tong
authors: Yuan
authors: Y
authors: Zhuang
authors: Quanming
authors: Q
authors: Zou
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D002478:Cells, Cultured; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007113:Immunity, Innate; D016130:Immunophenotyping; D020381:Interleukin-17 / Q000096:biosynthesis / Q000276:immunology*; D007378:Interleukins / Q000096:biosynthesis / Q000276:immunology*; D008207:Lymphatic Metastasis; D008213:Lymphocyte Activation / Q000187:drug effects; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology*; D016019:Survival Analysis; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D058504:Th17 Cells / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D000097043:Interleukin-22
chemical_list: D020381:Interleukin-17; D007378:Interleukins; D013755:Tetradecanoylphorbol Acetate; D000097043:Interleukin-22